



Article

Role of iRhom2 in Olfaction: Implications for Odorant Receptor Regulation and Activity-Dependent Adaptation

Stephanie A. Azzopardi ^{1,2,3,†} , Hsiu-Yi Lu ^{4,†} , Sebastien Monette ⁵ , Ariana I. Rabinowitsch ^{1,6} , Jane E. Salmon ^{7,8} , Hiroaki Matsunami ^{4,9,*} and Carl P. Blobel ^{1,2,3,6,8,*}

- ¹ Weill Cornell Medicine/Rockefeller University/Memorial Sloan-Kettering Cancer Center, Tri-Institutional MD-PhD Program, New York, NY 10021, USA; sta2017@med.cornell.edu (S.A.A.); arr2013@med.cornell.edu (A.I.R.)
- ² Physiology, Biophysics and Systems Biology Program, Weill Cornell Medicine, New York, NY 10021, USA
- ³ Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, NY 10021, USA
- ⁴ Department of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA; justice.lu@duke.edu
- ⁵ Tri-Institutional Laboratory of Comparative Pathology, Hospital for Special Surgery, Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine, New York, NY 10021, USA; monettes@mskcc.org
- ⁶ Department of Biochemistry, Cellular and Molecular Biology, Weill Cornell Medicine, New York, NY 10021, USA
- ⁷ Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY 10021, USA
- ⁸ Department of Medicine, Weill Cornell Medicine, New York, NY 10021, USA
- ⁹ Department of Neurobiology, Duke Institute for Brain Sciences, Duke University, Durham, NC 27710, USA
- * Correspondence: hiroaki.matsunami@duke.edu (H.M.); blobelc@hss.edu (C.P.B.)
- † These authors contributed equally to this work.
- ‡ These authors contributed equally to this work.



Citation: Azzopardi, S.A.; Lu, H.-Y.; Monette, S.; Rabinowitsch, A.I.; Salmon, J.E.; Matsunami, H.; Blobel, C.P. Role of iRhom2 in Olfaction: Implications for Odorant Receptor Regulation and Activity-Dependent Adaptation. *Int. J. Mol. Sci.* **2024**, *25*, 6079. <https://doi.org/10.3390/ijms25116079>

Academic Editor: Lindsey Schier

Received: 8 April 2024

Revised: 23 May 2024

Accepted: 27 May 2024

Published: 31 May 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The cell surface metalloprotease ADAM17 (a disintegrin and metalloprotease 17) and its binding partners iRhom2 and iRhom1 (inactive Rhomboid-like proteins 1 and 2) modulate cell–cell interactions by mediating the release of membrane proteins such as TNF α (Tumor necrosis factor α) and EGFR (Epidermal growth factor receptor) ligands from the cell surface. Most cell types express both iRhoms, though myeloid cells exclusively express iRhom2, and iRhom1 is the main iRhom in the mouse brain. Here, we report that iRhom2 is uniquely expressed in olfactory sensory neurons (OSNs), highly specialized cells expressing one olfactory receptor (OR) from a repertoire of more than a thousand OR genes in mice. *iRhom2*^{-/-} mice had no evident morphological defects in the olfactory epithelium (OE), yet RNAseq analysis revealed differential expression of a small subset of ORs. Notably, while the majority of ORs remain unaffected in *iRhom2*^{-/-} OE, OSNs expressing ORs that are enriched in *iRhom2*^{-/-} OE showed fewer gene expression changes upon odor environmental changes than the majority of OSNs. Moreover, we discovered an inverse correlation between the expression of iRhom2 compared to OSN activity genes and that odor exposure negatively regulates iRhom2 expression. Given that ORs are specialized G-protein coupled receptors (GPCRs) and many GPCRs activate iRhom2/ADAM17, we investigated if ORs could activate iRhom2/ADAM17. Activation of an olfactory receptor that is ectopically expressed in keratinocytes (OR2AT4) by its agonist Sandalore leads to ERK1/2 phosphorylation, likely via an iRhom2/ADAM17-dependent pathway. Taken together, these findings point to a mechanism by which odor stimulation of OSNs activates iRhom2/ADAM17 catalytic activity, resulting in downstream transcriptional changes to the OR repertoire and activity genes, and driving a negative feedback loop to downregulate iRhom2 expression.

Keywords: iRhom2 (inactive Rhomboid-like protein 2); ADAM17 (a disintegrin and metalloprotease 17); G-protein coupled receptor (GPCR); olfactory sensory neuron (OSN); olfactory receptor (OR); olfactory epithelium (OE); RNAseq; RNAscope in situ hybridization (ISH); single-cell RNAseq analysis

1. Introduction

Inactive Rhomboid 2 (iRhom2) and the related iRhom1 are seven membrane-spanning proteins that regulate the function of the cell surface metalloprotease a disintegrin and metalloprotease 17 (ADAM17) [1–11]. Both iRhoms are widely expressed, with two notable exceptions: iRhom1 expression is low or absent in myeloid cells, and iRhom2 expression is low or absent in the brain in mice, except for microglia [5,12]. ADAM17 has important roles in development and disease by regulating the TNF α -, EGFR- and other signaling pathways [12–17]. Since iRhom2 is required for the activity of ADAM17 in myeloid cells, mice lacking iRhom2 are protected from endotoxin shock and inflammatory arthritis [1,12], like mice lacking ADAM17 in myeloid cells [12]. Moreover, a double knockout mouse strain lacking both iRhom1 and 2 resembles ADAM17-knockout mice in that they die shortly after birth and have open eyes, heart valve defects and growth plate defects [5]. Proteomic analysis has discovered substrates for iRhom1 in the mouse brain [18], yet little is currently known about the role of iRhom2 in the nervous system.

Using an iRhom2-LacZ reporter mouse, we identified prominent iRhom2 expression in olfactory sensory neurons (OSNs), which was unexpected due to the otherwise low iRhom2 expression in the mouse brain. OSNs, unique neurons undergoing lifelong regeneration with a typical lifespan of six to eight weeks, detect odors via activation of olfactory receptors (ORs) and are directly exposed to the external environment, unlike the rest of the brain [19]. ORs, the largest family of G-protein coupled receptors (GPCRs), comprise about 400 genes in humans and about 1200 in mice [20]. During development, immature OSNs co-express multiple ORs, then undergo positive and negative selection, resulting in mature OSNs expressing a single OR type [21,22]. Furthermore, the OR composition in the olfactory epithelium (OE) undergoes activity-dependent sculpting, allowing neurogenesis and/or OSN survival to be modulated based on activity [23,24]. This process, often studied through unilateral naris occlusion in mice, enables adaptation to specific olfactory environments by adjusting the population of OSNs expressing individual ORs.

The selective iRhom2 expression in OSNs prompted questions about its OE function. We conducted histopathological analyses of the OE of *iRhom2*^{-/-} mice to assess changes in OSN maturation or turnover. We used an unbiased RNAseq approach to examine how iRhom2 inactivation affects OR and non-OR expression in the OE, focusing on activity-dependent genes. Additionally, we probed whether OR signaling activates iRhom2/ADAM17 by utilizing the HaCaT keratinocyte cells line, which endogenously expresses the receptor OR2AT4. Our findings provide evidence for a role of iRhom2 in OR landscape regulation and activity-dependent OSN expression programs.

2. Results

2.1. *iRhom2* Is Prominently Expressed in the Olfactory Sensory Neurons

Previous studies have demonstrated that iRhom2 is required for the maturation of ADAM17 and TNF α release from microglia but that it cannot support the maturation of ADAM17 in all major areas of the mouse brain in the absence of iRhom1 [5]. To learn more about the expression of iRhom2 in the brain, we utilized a reporter mouse, in which the expression of the LacZ gene is driven by the iRhom2 promoter. The iRhom2-LacZ reporter revealed little, if any expression in most of the brain, except for the olfactory bulb, where strong blue staining was evident (Figure 1A). Closer analysis of X-gal-stained sections of the olfactory bulb (OB) showed that the expression of iRhom2 was localized to a subset of glomeruli concentrated in the dorso-medial aspect of the OB (Figure 1B) [25]. The glomeruli of the OB contain the axon terminals of olfactory sensory neurons (OSNs) that originate in the olfactory epithelium (OE). X-gal-stained sections of the OE lining the nasal turbinates revealed high and specific expression of the iRhom2-LacZ reporter in the OSN layer (Figure 1C). The expression patterns of iRhom2 in the OE were independently corroborated by an mRNA in situ hybridization (ISH) analysis on sections of WT and *iRhom2*^{-/-} mice (Figure 1D). A similar analysis of iRhom1 expression by mRNA ISH (in situ hybridization) showed little, if any, expression in the OE, except in the submucosal layer

tion of the OB contains the axon terminals of olfactory sensory neurons (OSNs) that originate in the olfactory epithelium (OE). X-gal-stained sections of the OE lining the nasal turbinates revealed high and specific expression of the *iRhom2*-LacZ reporter in the OSN layer (Figure 1C). The expression patterns of *iRhom2* in the OE were independently corroborated by an mRNA in situ hybridization (ISH) analysis on sections of WT and *iRhom2*^{-/-} mice (Figure 1D). A similar analysis of *iRhom1* expression by mRNA ISH (in situ hybridization) showed little, if any, expression in the OE, except in the submucosal layer of sustentacular cells, in both WT and *iRhom2*^{-/-} mice. Moreover, we found similar levels of *iRhom1* mRNA in WT and *iRhom2*^{-/-} OE (Supplementary Figure S1). An analysis of publicly available single-cell RNAseq data [26] further confirmed the expression of *iRhom2* in mature and immature olfactory sensory neurons (mOSN and iOSNs, Figure 1F,G), whereas little *iRhom1* was expressed in these cells (Figure 1H). Other cell types, such as sustentacular cells and horizontal basal cells, also showed the expression of both *iRhom1* and *iRhom2*, consistent with the overlapping expression pattern of both *iRhoms* in most tissues in mice, except immune cells and the majority of cell types in the brain [5].




Figure 1. Characterization of the expression of *iRhom2* and *iRhom1* in olfactory sensory neurons (OSNs). (A) Whole brain from *iRhom2*-LacZ mice stained by X-gal reaction revealed that most brain tissue is negative for *iRhom2* expression except for a region in the olfactory bulb (OB, black arrow). (B) Sections of the OB from *iRhom2*-LacZ mice stained by X-gal reaction revealed *iRhom2* reporter expression in the dorsal-medial section of the OB (scalebar = 250 μm upper panel, 50 μm lower panel). (C) Sections of the olfactory epithelium (OE) of *iRhom2*-LacZ stained by X-gal reaction revealed *iRhom2* reporter expression in OSN cell bodies (black arrow, scalebar = 250 μm upper panel, 50 μm lower panel). (D) mRNA in situ hybridization (ISH) of olfactory epithelium with probe Mm-Rhbd2 confirmed high *iRhom2* mRNA levels in the OSNs of WT (pointed by black arrows), but not *iRhom2*^{-/-} mice (scalebars = 10 μm). *iRhom2*^{-/-} mice have no functional *iRhom2* protein, but express exons 1 and 2 as part of the targeting constructs [20], resulting in low levels of transcript presence in the *iRhom2*^{-/-} OE. (E) mRNA ISH staining of OE with probe Mm-Rhbd1 showed that no *iRhom1* is expressed in WT OSNs, although *iRhom1* is expressed in the sustentacular cells (indicated by black arrows, scalebars = 10 μm). (F–H) Analysis of single-cell RNAseq data of OE cells showed high expression of *iRhom2* in immature and mature OSNs (iOSN, mOSN) (F,G), but minimal expression of *iRhom1* in these cells (H). *iRhom1* is expressed in non-OSN cells in the OE, such as sustentacular cells (SUS).

of the targeting constructs [20], resulting in low levels of transcript presence in the *iRhom2*^{-/-} OE. (E) mRNA ISH staining of OE with probe Mm-Rhbd1 showed that *iRhom1* is expressed in WT OSNs, although *iRhom1* is expressed in the sustentacular cells (indicated by black arrows, scalebars = 10 μ m). (F–H) Analysis of single-cell RNAseq data of OE cells showed high expression of *iRhom2* in immature and mature OSNs (iOSN, mOSN) (F,G), but minimal expression of *iRhom1* in these cells (H). *iRhom1* is expressed in non-OSN cells in the OE, such as sustentacular cells (SUS).

To determine when *iRhom2* expression first appears in the OE during development, we assessed *iRhom2*-LacZ expression in the OE of newborn pups (Postnatal day 0, P0) and mice that were 2, 4 or 6 days old. We found minimal expression of the *iRhom2*-LacZ reporter at P0 but observed gradually increased expression over the first postnatal week from P2 to P6 (Supplementary Figure S2).

2.2. *iRhom2*^{-/-} Olfactory Epithelium Shows No Histopathologic Defects

Histological analysis of the OE by H&E, immunohistochemistry and in situ staining did not show any evident major defects in adult *iRhom2*^{-/-} mice compared to WT controls (Figure 2A). There was no significant difference in the pattern or percentage of cells labeled with the mature OSN marker OMP (olfactory marker protein, Figure 2B), immature OSN marker GAP43 (growth associated protein 43, Figure 2C), the proliferation marker Ki67 (Figure 2D) or the apoptosis marker cleaved caspase-3 (Figure 2E) in *iRhom2*^{-/-} versus WT mice. To determine whether *iRhom2* affects neurogenesis and/or longevity of OSNs, we injected bromodeoxyuridine (BrdU) intraperitoneally into 8–10 week old WT and *iRhom2*^{-/-} mice. There were no significant differences between the number of BrdU-labeled cells one day after injection and surviving cells at 28 days after injection between *iRhom2*^{-/-} versus WT OE (Supplementary Figure S3).




Figure 2. Histologic and immunohistochemical comparison between WT and *iRhom2*^{-/-} olfactory epithelium revealed no apparent phenotypic differences. (A) Sections stained with H&E revealed no evident difference in the appearance of the OSN cell body layer (yellow brackets) or axon bundles (scalebars = 20 μ m). (B,C) Staining with OMP to mark mature OSNs (B, yellow arrows) or GAP43 to mark immature OSNs (C, yellow arrows) and subsequent quantification revealed no differences in the number of mature or immature OSNs, respectively (scalebars = 20 μ m). (D,E) Staining of OE sections with antibodies against the proliferation marker Ki67 (D, black arrows) or against cleaved caspase-3 to identify apoptotic cells (E, black arrows) revealed no significant differences in proliferation or apoptosis, respectively (scalebars = 20 μ m). (F) RNAseq analysis of OE isolated from WT and *iRhom2*^{-/-} mice ($n = 12$ each) showed no difference in the expression of markers for mature OSN (mOSN) or immature iOSN (iOSN).

2.3. RNAseq GO Analysis

To investigate the role of *iRhom2* in the OE in a high-throughput, unbiased manner, we performed bulk RNAseq on OE tissue isolated from *iRhom2*^{-/-} and WT mice at different ages (5, 8, 10 and 30 weeks; 3 mice/ages/genotypes; combined *n* = 12 per genotype). Expression analysis of markers for distinct cell types present in the OE showed no major differences across mature or immature OSN markers (Figure 2F, mOSN, iOSN), consistent with the histological analyses described above.

To determine whether specific biological pathways are altered in *iRhom2*^{-/-} mice, we conducted a gene ontology (GO) analysis. Unexpectedly, the GO analysis showed enrichment of pathways for olfactory receptor activity, G-protein coupled receptor (GPCR) signaling and detection of stimuli involved in smell in the *iRhom2*^{-/-} OE (Figure 3A). As expected, we observed a significant downregulation in genes associated with innate immune responses, likely reflecting the well-characterized consequences of the loss of *iRhom2* on macrophage function, including the release of the pro-inflammatory cytokine TNF α [1,2,12] (Figure 3A, Supplementary Figure S4A,B). The genes contributing to the altered GO pathways are highlighted among other differentially expressed genes (FDR < 0.1, Figure 3B). Cell types that contributed to the downregulated GO terms were mainly non-OSN cells (immune, sustentacular ventral cells, HBCs (horizontal basal cells), Figure 3C, Supplementary Figure S4A). In contrast, contributions to the upregulated GO terms derived mainly from mOSNs and iOSNs (Figure 3D).

2.4. Activation of *iRhom2*/ADAM17 by OR Signaling in a Non-OSN Cell Type

Among the top pathways enriched in *iRhom2*^{-/-} OE, OR activity and GPCR signaling were particularly interesting, since *iRhom2* has been implicated in the crosstalk between the GPCR receptor for lipophosphatidic acid (LPA) and EGFR/ERK (extracellular signal-regulated kinases) signaling in mouse embryonic fibroblasts [27]. Moreover, signaling through many GPCRs is known to stimulate the activity of ADAM17 [28–33]. In addition, the stimulation of GPCRs in several cell types, including keratinocytes, can activate ADAM17-dependent shedding of EGFR ligands (e.g., HB-EGF, heparin-binding epidermal growth factor like growth factor) and thus the EGFR/ERK pathway [27,29,34] (see model in Figure 4A). ORs are GPCRs, yet it is not known whether ORs activate *iRhom2*/ADAM17. Primary mouse OSNs are challenging to isolate and culture and we are not aware of available OSN cell lines. Therefore, in order to study whether OR signaling activates *iRhom2*/ADAM17, we turned to a cell line that expresses an OR with a known odorant ligand and is easy to culture. Specifically, we employed the human keratinocyte HaCaT cell line, which expresses the OR OR2AT4, which can be activated by addition of its odorant ligand, Sandalore. As a positive control for GPCR/ERK crosstalk, LPA (lysophosphatidic acid) was utilized; this is known to activate *iRhom2* and ADAM17 [21,25]. Treatment of HaCaTs with LPA (10 μ M) for 5 min caused rapid phosphorylation of ERK1/2 that was prevented by the metalloprotease inhibitor marimastat (MM, 5 μ M) (Figure 4B). Treatment of HaCaT cells with 1 mM Sandalore for 5 min also triggered rapid phosphorylation of ERK1/2, in agreement with a previous report [35]. ERK phosphorylation induced by Sandalore was blocked by treatment with marimastat (Figure 4B), indicating that OR OR2AT4 activates a metalloprotease, most likely *iRhom2*/ADAM17, to elicit crosstalk leading to phosphorylation of ERK1/2.

2.5. Change in Differential Expression of ORs in *iRhom2*^{-/-} over Time

Bulk RNAseq revealed that a subset of 14 ORs were significantly upregulated (red dots, FDR (false discovery rate) < 0.05) and 16 ORs were significantly downregulated (blue dots, FDR < 0.05) in the *iRhom2*^{-/-} OE, whereas most ORs (grey dots, >1000 ORs detected) were not differentially expressed (DE) (Figure 5A, *n* = 12 data from combined ages 5, 8, 10 and 30 weeks). We found that the differential expression of these 30 ORs varies across ages (5, 8, 10 and 30 weeks, Figure 5B). A pairwise correlation for ORs that were significantly DE between *iRhom2*^{-/-} and WT mice (FDR < 0.05) indicated substantial correlations between 5

To determine whether specific biological pathways are altered in *iRhom2*^{-/-} mice, we conducted a gene ontology (GO) analysis. Unexpectedly, the GO analysis showed enrichment of pathways for olfactory receptor activity, G-protein coupled receptor (GPCR) signaling and detection of stimuli involved in smell in the *iRhom2*^{-/-} OE (Figure 3A). As expected, we observed a significant downregulation in genes associated with innate immune responses, likely reflecting the well-characterized consequences of the loss of *iRhom2* on macrophage function, including the release of the pro-inflammatory cytokine TNF α [12,12] (Figure 3A, Supplementary Figure S4A–B). The genes contributing to the altered GO pathways were highlighted among other differentially expressed genes (FDR < 0.1, Figure 3B). Cell types that contributed to the downregulated GO terms were mainly non-OSNs (cells immune, sustentacular, ventral cells, HBCs (horizontal basal cells), DE at 50 weeks (Supplementary Figure S5)). The degree of differential expression for OR changes with age, as can be seen by following the logFC for the DE ORs (FDR < 0.05) at each age over time (Supplementary Figure S5) (Figure 3D).





Figure 3. Bulk RNAseq GO analysis of *iRhom2*^{-/-} OE versus WT OE. (A) GO analysis revealed pathways upregulated in the *iRhom2*^{-/-} OE were exclusively related to OR/GPCR/GPCRs signaling, while pathways downregulated were related to innate immune function. (B) Volcano plot of genes differentially expressed between WT and *iRhom2*^{-/-}. Individual genes that contributed to the GO terms are labelled in pink (upregulated) and green (downregulated) plotted by the logFC and $-\log(\text{FDR})$. Only genes with FDR < 0.1 were considered for the GO analysis, all others are labelled in gray. (C,D) Aggregated counts of the top 4 GO terms in WT and *iRhom2*^{-/-} were plotted on a UMAP of OE cell types. Downregulated GO terms in the *iRhom2*^{-/-} OE are predominantly localized to non-neuronal tissues, including immune cells (C). Upregulated GO terms in the *iRhom2*^{-/-} OE are predominantly localized to mOSNs and iOSNs (D).

2.6. *iRhom2* Expression Negatively Correlates with Neuronal Activity

We analyzed a publicly available single-cell RNAseq database of mouse OSNs [36] and stratified OSNs into five subsets, based on the expression level of *iRhom2*, including a subset of OSNs with no detectable *iRhom2* (referred to as *iRhom2*⁻). In the subset with no detectable *iRhom2* expression, the top upregulated transcripts included the neuronal activity genes *S100a5*, *Dlg2*, *Pcp4l1*, *Kirrel2* and *Lrrc3b* [37–39] (Figure 6A). A step-wise inverse correlation exists between OSNs with increasing levels of *iRhom2* and reduced *S100a5* expression (Figure 6B). On UMAP (Uniform Manifold Approximation and Projection), OSNs with the highest *S100a5* expression overlapped with those showing the lowest *iRhom2* expression



2.5. Change in Differential Expression of ORs in *iRhom2*^{-/-} over Time

Bulk RNAseq revealed that a subset of 14 ORs were significantly upregulated (red dots, FDR (false discovery rate) < 0.05) and 16 ORs were significantly downregulated (blue dots, FDR < 0.05) in the *iRhom2*^{-/-} OE, whereas most ORs (grey dots, >1000 ORs detected) were not differentially expressed (DE) (Figure 5A and Supplementary Figure S5). We found that the differential expression of these 30 ORs varies across ages (5, 8, 10 and 30 weeks, Figure 5B). A pairwise correlation for ORs that were significantly DE between *iRhom2*^{-/-} and WT mice (FDR < 0.05) indicated substantial correlations which in turn results in the shedding of HB-EGF and activation of ERK1/2 and stimulation of cell survival and/or proliferation (Figure 4B). Stimulation of human HaCaT cells with Sandalore (Sand) stimulates phosphorylation of ERK1/2 and p-ERK signal can be prevented by addition of the metalloprotease inhibitor marimastat (MM, 5 μ M), which blocks the activity of ADAM17 (Figure 4B). Stimulation of HaCaT cells with the GPCR-agonist LPA results in a similar increase in p-ERK1/2, which can be blocked by MM (5 μ M). Densitometric quantification (lower panels) show significant reduction in p-ERK signal of the DMSO or MM conditions compared to Sandalore- or LPA-treated conditions (results of Student's *t*-test indicated, *n* = 4).




Figure 5. Differentially expressed (DE) ORs in *iRhom2*^{-/-} OE versus WT OE. (A) Volcano plot shows the distribution of DE ORs upregulated (14 ORs, red) or downregulated (16 ORs, blue) in the *iRhom2*^{-/-} OE with FDR < 0.05 (*n* = 12 per genotype). Most ORs are not differentially expressed in the *iRhom2*^{-/-} OE (>1000 ORs, grey). (B) Line graph showing the expression of upregulated (red) or downregulated (blue) ORs across ages at week 5, 8, 10 and 30. Results of Student's *t*-tests are indicated above each time point. (C) A pairwise Pearson correlation of OR logFC across the different time points shows higher correlation of DE ORs at closer age ranges and lower correlation between larger age ranges.

2.6. *iRhom2* Expression Negatively Correlates with Neuronal Activity

We analyzed a publicly available single-cell RNAseq database of mouse OSNs [36] and stratified OSNs into five subsets, based on the expression level of *iRhom2*, including a subset of OSNs with no detectable *iRhom2* (referred to as *iRhom2*⁻). In the subset with no detectable *iRhom2* expression, the top upregulated transcripts included the neuronal

with no detectable *iRhom2* (single-cell RNAseq, see above), see above) expressed at lower levels in the *iRhom2*^{-/-} OE, with significantly lower expression of *Dlg2*, *Lrrc3b* and *Kirrel2* (Supplementary Figure S7), suggesting that *iRhom2* activity is required for the normal expression of these genes. Taken together, these findings suggest that *iRhom2* and most likely ADAM17 have a functional role downstream of OR signaling that may first promote the expression of activity genes but subsequently feeds back to downregulate *iRhom2*.




Figure 6. *iRhom2* expression inversely correlates with activity genes. (A) Based on single-cell RNAseq RNA analysis of mOSNs and OSNs with no detectable *iRhom2* expression, the enriched transcripts were ranked by activity genes (*S100a5*, *Dlg2*, *Pcp4l1*, *Kirrel2*, *Lrrc3b*, *Fam213a*, *573040307RIK*, *Epha5*, *Rasgrp4*, *Fetub*, and *Shca*), pointed out by red arrows (A). (B) There is an inverse correlation between the levels of *iRhom2* and *S100a5* expression (B). (C) UMAP shows that OSNs in the region with highest *S100a5* expression correlate to the OSNs with the lowest *iRhom2* expression. (D) Analysis of single-cell RNAseq data from Tsukahara et al. [36] shows that *iRhom2* expression is significantly reduced upon acetophenone (ACE) exposure for 2 h, whereas *S100a5* expression is significantly increased upon ACE exposure. The solvent is the vehicle control dipropylene glycol. (E) UMAP from single-cell RNAseq of OSNs dissected from naris occlusion experiments. Data are integrated computationally while retaining their open or closed naris tags to create a single UMAP (left panel). *iRhom2* expression is most prominent in the OSNs from the closed naris (middle panel), while *S100a5* expression is most prominent in the OSNs from the open naris (right panel).

To understand why *iRhom2* expression is inversely correlated with OSN activity genes, we examined a dataset generated from single-cell Act-seq of the OSNs of mice that were exposed to the odorant acetophenone or solvent only for 2 h [36]. Single-cell Act-seq is a technique that identifies transcriptomic changes due to neuronal activation. We found *iRhom2* expression significantly decreased ($p = 0.028$), whereas *S100a5* expression significantly increased ($p < 0.01$) in OSNs activated by acetophenone; however, exposure to the control solvent did not significantly affect *iRhom2* expression and had a minimal effect on *S100a5* expression (Figure 6D). Furthermore, analysis of a single-cell RNAseq dataset of OSNs from the open and closed naris of naris occlusion experiments showed that the OSN cluster in UMAP with the lowest *S100a5* activity had the highest *iRhom2* expression and vice versa (Figure 6E). Collectively, these findings suggest that *iRhom2* is downregulated by odor stimulation. However, all five activity genes enriched in OSNs with no detectable *iRhom2* (single-cell RNAseq, see above) were expressed at lower levels in the *iRhom2*^{-/-} OE, with significantly lower expression of *Dlg2*, *Lrrc3b* and *Kirrel2* (Supplementary Figure S7), suggesting that *iRhom2* activity is required for the normal expression of these genes. Taken together, these findings suggest that *iRhom2* and most likely ADAM17 have a functional role downstream of OR signaling that may first promote the expression of activity genes but subsequently feeds back to downregulate *iRhom2*.

2.7. OSNs Expressing ORs Upregulated in *iRhom2*^{-/-} Maintain Unusually Stable Gene Expression Amid Environmental Odor Changes

We examined whether OR populations that are upregulated or downregulated in the *iRhom2*^{-/-} OE exhibit unique gene regulatory patterns in response to environmental odor changes using existing scRNAseq data derived from unilateral naris occlusion experiments in mice [36]. To determine the overall transcriptomic changes between the open and closed naris, we conducted pairwise Euclidean distance measurements between every mOSN expressing the same ORs, as outlined in Figure 7A. Euclidean distance is a readout of overall gene expression change in the OSNs between conditions. The Principle Component Analyses (PCA) in Figure 7A provide examples of ORs with relatively small (*Olfrs* 1346 and 536) or large (*Olfrs* 1366, 655 and 1028) Euclidean distances between the open and closed naris. Most OSNs, including the OR subsets that are downregulated in the *iRhom2*^{-/-} OE (KO- ORs), showed significant gene expression changes upon naris occlusion (Figure 7B). This includes reduced expression of known neuronal activity genes such as *S100a5* (Figure 7C) and increased expression of *iRhom2* (Figure 7D). In contrast, ORs enriched in *iRhom2*^{-/-} (KO+ ORs) have relatively small Euclidean distances (KO+ OR in Figure 7B) and show minimal change in *S100a5* (Figure 7C) and *iRhom2* (Figure 7D) expression despite naris occlusion. In an effort to explore the impact of naris occlusion on the olfactory receptor repertoire, we next examined the fold change in the expression of ORs between nares (Figure 7E). Our findings align with previous research [23], indicating a significant decrease in most OR transcript levels following naris occlusion. However, again, the mOSNs expressing ORs upregulated in the *iRhom2*^{-/-} were the exception to the rule as the group exhibited no significant change in OR transcript levels between the open and closed naris. This phenotype underscores the specialized regulatory mechanisms of the subset of ORs enriched in *iRhom2*^{-/-}, implying their independence from activity-dependent gene expression modifications. Overall, these results point to critical roles of *iRhom2* in the fine-tuning of the olfactory landscape and activity in response to odor stimulation and deprivation.

2.8. Gene Expression Changes in *iRhom2*^{-/-} OE Mimic Changes Occurring in Naris Occlusion

Previous work by Tsukahara et al. [36] characterized a subset of genes upregulated by naris occlusion (GEP low) and a subset downregulated by naris occlusion (GEP high). We found that the same subset of genes upregulated by naris occlusion was significantly upregulated in the *iRhom2*^{-/-} OE (Figure 8A). The gene subset downregulated by naris occlusion was also downregulated in the *iRhom2*^{-/-} OE at age 10 weeks and 30 weeks (Supplementary Figure S8). Moreover, a group of genes described in a review article [40] to be consistently up- or downregulated in an activity-dependent manner across several unilateral naris occlusion studies responded in a similar manner to the inactivation of *iRhom2* as in the occluded naris. The genes that are downregulated by activity and upregulated upon naris occlusion are also upregulated in the *iRhom2*^{-/-} OE (Figure 8B). These results indicate that gene expression changes in *iRhom2*^{-/-} OE mirror changes occurring after naris occlusion, further corroborating that *iRhom2* regulates activity-dependent gene transcription.




Figure 7. Odor-dependent regulation of *iRhom2* and *S100a5* expression. (A) Principal Component Analysis (PCA) of single-cell RNA-seq data from the naris occlusion experiment by Tsukahara et al. [36]. Scheme of pairwise Euclidean distance comparison (top left indicated by black double-headed arrows) and representative PCA for ORs involved in OE (KO+ OR (KO+OR) and ORs reported in OE (KO-OR) (KO-OR). The pairwise Euclidean distance comparison is the difference between the distance between the closed and open naris expression. ORs 1366 and 655 are examples of KO+ ORs with small Euclidean distances (2.6 and 2.8, respectively), representing minimal transcriptional differences upon naris occlusion. ORs 1366, 655 and 1028 are examples of KO- ORs with relatively large Euclidean distances (6.7, 4.4 and 6.2, respectively), representing larger transcriptional differences upon naris occlusion. (B) Violin plots and kernel density estimate (kde) plots of Euclidean distances show that KO+ ORs (red) cluster around low Euclidean differences, while KO- ORs (blue) have higher Euclidean differences. (C) KO+ ORs show minimal changes in *S100a5* expression between naris occlusion, while KO- ORs show negative fold change in *S100a5* expression with naris occlusion. Gray and blue arrows indicate the direction of change. (D) KO+ ORs show minimal changes in *iRhom2* expression between naris occlusion, while KO- ORs show negative fold change in *iRhom2* expression with naris occlusion. Gray and blue arrows indicate the direction of change. (E) KO+ ORs show minimal changes in *iRhom2* expression between naris, while all other ORs show negative fold change in *iRhom2* expression with naris occlusion. Gray and blue arrows indicate the direction of change.

2.8. Gene Expression Changes in *iRhom2*-/- OE Mimic Changes Occurring in Naris Occlusion

Previous work by Tsukahara et al. [36] characterized a subset of genes upregulated by naris occlusion (GEP low) and a subset downregulated by naris occlusion (GEP high). We found that the same subset of genes upregulated by naris occlusion was significantly upregulated in the *iRhom2*-/- OE (Figure 8A). The gene subset downregulated by naris occlusion was also downregulated in the *iRhom2*-/- OE at age 10 weeks and 30 weeks (Supplementary Figure S8). Moreover, a group of genes described in a review article [40] to be consistently up- or downregulated in an activity-dependent manner across several unilateral naris occlusion studies responded in a similar manner to the inactivation of *iRhom2* as in the occluded naris. The genes that are downregulated by activity and upregulated upon naris occlusion are also upregulated in the *iRhom2*-/- OE (Figure 8B).




Figure 8. Gene sets upregulated by naris occlusion are also upregulated in *iRhom2*^{-/-} OE. (A) The gene set characterized by Tsuchihara et al. [36] as being upregulated upon naris occlusion (GEP low) is also upregulated in the *iRhom2*^{-/-} OE versus WT OE. Of 12 pd2 geneotypes, 9 are significantly different (p < 0.001) from the gene set downregulated upon naris occlusion (GEP high) or not significantly affected (na). (B) Similar observations were made with gene sets downregulated by odor activity as characterized by the meta-analysis by Wang et al. [40], which were upregulated in the *iRhom2*^{-/-} OE versus WT.

3.3 Discussion

The observation of elevated expression of *iRhom2* in the olfactory bulb led to this study aiming to elucidate the role of *iRhom2* in olfactory signaling. The *iRhom2*^{-/-} OE confirmed the presence of *iRhom2* in OSNs. Independent verification came from RNA-Seq and single-cell RNA-Seq showing *iRhom2* mRNA but not *iRhom1* mRNA in the OSNs. The selective presence of *iRhom2* in the OSNs was surprising as *iRhom1* is the primary *Rhom* in most mouse brain areas [5,18], while *iRhom2* is dominant in immune cells [22,21]. *iRhom2* gene knockout caused no evident defects in OE histopathology versus WT controls, maintaining similar cell type markers, including immature and mature OSNs and proliferation or apoptosis markers.

Our bulk RNA-Seq analysis revealed a small subset of 50 ORs that are differentially expressed in *iRhom2*^{-/-} OE (FDR < 0.05), with approximately half upregulated and half downregulated. However, most ORs were not differentially expressed in the *iRhom2*^{-/-} OE. Given that OR level differences in RNA-Seq are thought to faithfully reflect OSN quantity variances expressing particular ORs in different mouse strains [41], *iRhom2* appears to regulate specific OSN abundance in the OE. This change in OR populations might also in turn affect the ability to detect and discern different odors as OR abundance could influence odor threshold [42]. Additionally, the influence of other chemosensory inputs such as trigeminal nerves could also be considered in understanding the role of *iRhom2* in chemosensation [43].

The genes upregulated in *iRhom2*^{-/-} OE align with the genes showing increased expression upon naris occlusion, suggesting a connection between odor signaling and *iRhom2*. The fine-tuning of the OSN repertoire through activity-dependent longevity control and/or OR gene selection is an evolutionary strategy believed to enhance an organism's environmental adaptability [36]. Stimulating specific ORs can either promote or inhibit their OSN survival [44]. Additionally, odor stimulation can boost the number of newly formed OSNs

that express odor-responsive ORs [24]. Enhancing the abundance of particular OSNs is thought to make the OE more responsive to odorant signaling, which can improve the organism's ability to forage for food, find mates and avoid predators, which are all key activities that offer a survival advantage. In contrast, reducing the abundance of other OSN subsets through odor stimulation is seen as an adaptation mechanism to specific olfactory environments, favoring the survival of non-stimulated neurons for increased sensitivity to new odors and stimuli. These insights, combined with the role of *iRhom2* in modulating OR abundance and activity-dependent transcription, indicate multiple signaling pathways activated by odor stimulation and *iRhom2* function.

Another perspective involves the development and maturation of the olfactory system. Although the present study used mice with mature olfactory organs (age 5–30 weeks), it is noteworthy that olfactory discrimination capabilities develop prenatally in humans [45] and mice [46]. While fetal and neonatal development is not directly relevant here, it provides context for understanding olfactory system maturation. Investigating the expression pattern and consequences of *iRhom2*-deletion in murine fetuses and neonates could present an interesting avenue for future studies [42].

Interestingly, previously reported single-cell sequencing of OSNs revealed an inverse relationship between *iRhom2* expression and neuronal activity-induced gene upregulation. To reconcile our observation of *iRhom2* expression starting postnatally, presumably upon exposure to air flow or odorants, yet being negatively influenced by neuronal activity in mature OSNs, we propose some possible explanations. Firstly, *iRhom2* expression in embryonic OSNs might be activated by chemicals in the amniotic fluid or postnatally by exposure to air flow or odorants or both. Alternatively, the initial onset of *iRhom2* expression in OSNs during the first postnatal week could be determined by the age of the mouse or of individual OSNs, independent of odor stimulation. Secondly, *iRhom2* expression could become regulated by OR activity as a negative feedback mechanism in adult mice.

How can OR stimulation influence *iRhom2* activity and expression? Since ORs are part of the GPCR family, we hypothesize that OR signaling activates *iRhom2*/ADAM17, similar to the established GPCR-ADAM17-EGFR/ERK signaling pathway [16,27,29,47]. Prior research has highlighted the essential role of metalloproteases, especially ADAM17, in facilitating an interaction between GPCRs and the EGFR, which subsequently regulates cell migration and proliferation [32,34,47–49]. The crosstalk between a GPCR, *iRhom2*/ADAM17 and EGFR forms a triple membrane-spanning signaling pathway, crucial for physiological processes like hair growth, relying on ADAM17-mediated EGFR activation post-GPCR stimulation by LPA [34]. Additionally, several GPCRs have been associated with the ADAM17-driven release of the EGFR ligand TGF α [28]. Despite ORs being the largest GPCR family [20], their involvement in *iRhom2*/ADAM17-mediated OR signaling within OSNs remains unexplored. Intriguingly, our data and previous studies indicate that OR stimulation by odorants can trigger ERK phosphorylation rapidly [50], suggesting a similar triple membrane-spanning pathway might exist in OSNs. It is also recognized that ORs are expressed in various cells beyond OSNs, such as keratinocytes and macrophages [35,51,52]. This study presents initial evidence that stimulating the keratinocytes OR OR2AT4 enhances ERK activation via a metalloprotease, most likely *iRhom2*/ADAM17, akin to LPA-induced stimulation [27] (see model in Figure 9). Further studies will be necessary to corroborate whether OR signaling in primary OSNs also activates *iRhom2*/ADAM17.

Given the known role of *iRhom2* in immune cells, it was not surprising that we found that the pathways downregulated in the *iRhom2*^{-/-} OE related to the innate immune response. Since OSNs are not known to have a role in innate immunity, this likely reflects the absence of *iRhom2* function in the immune cells of the OE. Since all the mice in this study were kept under homeostatic, non-inflammatory conditions, we would not expect a difference in the OSN health or survival. Future studies will be necessary to determine whether *iRhom2*^{-/-} OSNs may be protected from olfactory inflammation and damage and show enhancement of survival in an olfactory injury model.




Figure 9. Schematic of OR/iRhom2/ADAM17 pathway resulting in catalytic activity of the iRhom2/ADAM17 protease complex and transcriptional changes in activity genes, nares occlusion genes and iRhom2. Question marks indicate currently unknown mechanisms that are at least linked to the cytoplasmic domain of iRhom2 and indicate possible phosphorylation of OR or OR activation, the circle with a black slash symbol indicates that *iRhom2* mRNA and iRhom2 protein are not present in the *iRhom2*^{-/-} mice.

Taken together, our studies have identified a role for iRhom2 in the pathway of OR regulation. In the *iRhom2*^{-/-} mice, the activity of ORs is reduced. Since OSNs are not known to have a direct relationship between *iRhom2* mRNA levels and OR activity, gene expression of *iRhom2* (e.g. in the *Dlg2* *Kirrel 2* cells) in the OR-stimulated active OSNs study *iRhom2* expression possibly to limit their odor responsiveness as part of an activity-dependent desensitization strategy. Nares occlusion in single-cell RNA-seq data further revealed that the deprivation of OR stimulation in the closed nares causes an increase in *iRhom2* mRNA, potentially sensitizing inactive OSNs. Additionally, specific gene sets identified as upregulated in the occluded nares have also been elevated in *iRhom2*^{-/-} mice. Together, these findings support a model where OR stimulation activates iRhom2/ADAM17 to process an EGFR ligand (or other proteins) leading to (a) upregulation of OSN activity genes and (b) reduced expression of gene sets that are enriched in the occluded nares (Figure 9). This activity gene expression (e.g. *Dlg2*, *Kirrel 2*) implies that the most active OSNs reduce *iRhom2* expression, possibly to limit their odor responsiveness, as part of an activity-dependent desensitization strategy. Nares occlusion in single-cell RNA-seq data further reveal that deprivation of OR stimulation in the closed nares causes an increase in *iRhom2* mRNA, potentially sensitizing inactive OSNs. Additionally, specific gene sets identified as upregulated in the occluded nares [36,40] are also elevated in *iRhom2*^{-/-} mice. Together, these findings support a model where OR stimulation activates iRhom2/ADAM17 to process an EGFR ligand (or other proteins) leading to (a) upregulation of OSN activity genes and (b) reduced expression of gene sets that are enriched in the occluded nares (Figure 9). Thus, the rheostat model might not apply to a small number of atypical OSNs expressing ORs, which may trigger a negative feedback mechanism that reduces *iRhom2* transcription to upregulate in *iRhom2*^{-/-}. Rather, our data suggest distinct regulatory models depending on which OR is expressed in a given OSN.

In summary, this study reveals that iRhom2 regulates the OR repertoire of the olfactory epithelium and the gene expression profiles of OSNs in an activity-dependent manner. Odorant stimulation of ORs likely activates iRhom2/ADAM17 catalytic activity, which in turn upregulates activity genes but downregulates the expression of occlusion genes, maintaining a balance between olfactory sensitization and desensitization. Why are the subset of ORs that are upregulated in *iRhom2*^{-/-} resistant to the effects of odor deprivation? Intriguingly, OSNs expressing these upregulated ORs in *iRhom2*^{-/-} resulting in the transcriptional regulation of activity-dependent genes. A negative

feedback mechanism exists by which active OSNs can downregulate *iRhom2* expression to reduce the sensitivity of the OSNs to activity-dependent changes. *iRhom2* may thereby control the sensitization or desensitization of OSNs to odorant stimulation. Additional research will be required to deepen our understanding of *iRhom2*'s function in modulating OSN abundance and function.

4. Materials and Methods

4.1. Mice

We employed *iRhom2* KOMP ([53] Rhbdf2^{tm1b(KOMP)Wtsi}, referred to as *iRhom2*^{-/-}, 129Sv, C57BL/6 mixed genetic background) [53], in which the expression of LacZ is driven by the endogenous *iRhom2* promoter.

4.2. X-Gal Staining

Adult *iRhom2*^{-/-} or *iRhom1*^{-/-} mice of different ages (as indicated) were sacrificed by CO₂ euthanasia for adults or decapitation for neonates following the AVMA Guidelines for the Euthanasia of Animals. Heads were fixed in 4% PFA overnight at 4 °C, decalcified in 0.5 M EDTA, pH 7.4 (Boston Bioproducts, Milford, MA, USA, BM-711) for 2 weeks at 4 °C and cryoprotected in 30% sucrose/PBS for 2 days at 4 °C. Heads were then flash frozen in OCT (Sakura Finetek, Torrance, CA, USA, 4583) and sectioned on a cryostat (Leica Biosystems, Deerpark, IL, USA, CM3050S) using high-profile disposable blades 818 (Leica Biosystems, Deerpark, IL, USA, 14035838383) at −19 °C at 10 µm thickness. X-gal solution is composed of 100 mmol/L sodium phosphate, 1.3 mmol/L MgCl₂, 3 mmol/L potassium ferricyanide, 3 mmol/L potassium ferrocyanide and 1 mg/mL X-gal powder (Apex Bio Tech LLC, Houston, TX, USA, A2539, Batch # 2) dissolved into DMSO, diluted into ddH₂O. Sections were stained in X-gal solution for 17 h, washed with ddH₂O, counterstained with Eosin B, dehydrated, placed on superfrost plus microscope slides (Cardinal Health, Dublin, OH, USA, M6146-PLUS) and covered with coverslips.

4.3. RNA In Situ Hybridization

Specimens from WT and *iRhom2*^{-/-} mice 8–12 weeks old were fixed in 10% neutral buffered formalin for 7 days, decalcified in a freshly prepared 14% EDTA pH 7.2–7.4 solution (EDTA 99% pure, Thermo Scientific, Cat # 118432500, Sodium hydroxide 10.0N, LabChem Cat # LC245002) for 21 days, processed routinely in alcohol and xylene, and embedded in paraffin. Five micron thick sections were cut from the paraffin blocks and mounted on glass slides. Chromogenic in situ hybridization was performed on an automated stainer (Leica Bond RX, Leica Biosystems, Deer Park, IL, USA) with RNAscope 2.5 LS Assay Reagent Kit-Red (Advanced Cell Diagnostics, Newark, CA, USA, Cat. # 322150) and Bond Polymer Refine Red Detection (Leica Biosystems, Buffalo Grove, IL, Cat. # DS9390) following the manufacturer's standard protocol. Slides were stained with appropriate RNA scope 2.5 LS Probes ordered from Advanced Cell Diagnostics (Newark, CA, USA) as follows: Mm-Rhbdf2 (*iRhom2*), Cat No. 476168 (targeting region 760–1667 of NM_172572.3), Mm-Adam17, Cat No. 479518 (targeting region 1383–2325 of NM_009615.6) and Mm-Rhbdf1, Cat No. 476158 (targeting region 414–1421 of NM_010117.2). A positive control probe detecting a housekeeping gene (mouse *Ppib*, Advanced Cell Diagnostics, cat # 313918) and a negative control probe detecting the bacterial (*Bacillus subtilis*) *dapB* gene (Advanced Cell Diagnostics, Cat. # 312038) were used to confirm adequate RNA preservation and detection, and the absence of non-specific signal, respectively. The chromogen was fast red and the counterstain hematoxylin. Positive RNA hybridization was identified as discrete, punctate chromogenic red dots under brightfield microscopy.

4.4. Treatment of Keratinocytes with Sandalore and Phospho-ERK Western Blot

HaCaTs were cultured in DMEM with 10%FCS and 1%P/S. Cells were plated at 100,000 cells/well in full media in a 12-well format. The next day, cells were serum starved for 17 h in DMEM without FCS. After starvation, the cells were washed once with pre-

warmed PBS and treated with Sandalore (1 mM; Perfumer Supply House, Danbury, CT, USA, CAS#65113-99-7) diluted in DMSO, or DMSO-only vehicle, for 5 min at 37 °C. Cells were removed from the incubator, washed 2X with ice cold PBS and lysed in 100 µL/well of lysis buffer composed of 1% Triton-X100, protease inhibitor cocktail (1:500; Roche, Basel, Switzerland), marimastat (5 µM; Sigma Aldrich, St. Louis, MO, USA, 154039-60-8), 1,10-Phenanthroline (10 mM; Sigma Aldrich, St. Louis, MO, USA, P9375-259), Sodium Fluoride (10 mM) and Sodium Orthovanadate (2 mM). Next, 6x SDS sample buffer and 50 mM DTT were added to all samples. Samples were boiled for 7 min at 95 °C. Then, 20 µL of sample was run per lane on 10% SDS-polyacrylamide gels. Gels were transferred in a Trans-blot SD semi-dry transfer cell (BioRad, Hercules, CA, USA, 1703940) onto BioTrace Nitrocellulose membranes (Cytiva, Marlborough, MA, USA, 66485). Membranes were blocked in 5% milk, incubated in p-ERK antibody (1:1000; Cell Signaling Technologies, Danvers, MA, USA, 9101S) or ERK1/2 antibody (1:5000; Sigma Aldrich, St. Louis, MO, USA, M5670) overnight at 4 °C and stained with HRP-conjugated anti-rabbit IgG secondary antibody (1:5000; Promega, Madison, WI, USA, W401B) for 30 min at room temperature. We used an ECL detection system (Cytiva, Marlborough, MA, USA, RPN2106) and a Chemidoc image analyzer (Bio-Rad, Hercules, CA, USA) to expose the blot for 30 s by chemiluminescence.

4.5. Immunohistochemistry

IHC was performed on a Leica Bond RX automated stainer using Bond bulk reagents (Leica Biosystems, Buffalo Grove, IL, USA) and a polymer detection reagent kit (DS9800, Novocastra Bond Polymer Refine Detection, Leica Biosystems). The chromogen was 3,3-diaminobenzidine tetrachloride (DAB), and sections were counterstained with hematoxylin. For Ki67, slides were heat induced at pH 9.0 for epitope retrieval, stained with anti-Ki67 (Cell Signaling, Danvers, MA, USA, 12202, 1:500) and secondarily stained with Leica Biosystems DS9800 kit, reagent #3, no dilution. For cleaved caspase-3, slides were heat induced at pH 6.0 for epitope retrieval, stained with anti-cleaved caspase-3 (1:250, Cell Signaling, 9661) and secondarily stained with Leica Biosystems DS9800 kit, reagent #3, no dilution.

4.6. Slide Scanning and Cellular/Subcellular Quantification

Slides were scanned by brightfield imaging at 40X magnification on the Axioscan 7 Microscope Slide Scanner (Zeiss, Oberkochen, Germany). Images were analyzed using Qupath 0.4.1 [54]. The olfactory epithelium layer was annotated manually and analyzed. All cells were detected and included in the following analysis using Qupath Cell Detection algorithm. For RNA ISH analysis, transcripts were detected using Qupath Subcellular Detection algorithm with an expected, minimum and maximum spot size of 1.2, 0.5 and 1.2 µm, respectively. The number of dots per cell included individual dots and estimated dot numbers from clusters. For Ki-67 and cleaved caspase-3 quantification, positive cell detection algorithm was used.

4.7. BrdU Injection, Tissue Harvest and Staining

BrdU (Sigma-Aldrich, St. Louis, MO, USA, B9285) was diluted to 10 mg/mL solution in sterile PBS and aliquoted for storage at −80 °C. Mice were injected with 100 mg/kg BrdU intraperitoneally and sacrificed either 1 day or 28 days post-injection. Heads were harvested for fixation, decalcification, FFPE and sectioning. Slides were heat induced at pH 9.0 for epitope retrieval, stained with anti-BrdU (Abcam, Cambridge, UK, ab6326, 1:250), post primary stained with Vector Laboratories AI 4001 (1:100) and secondarily stained with Leica Biosystems DS9800 kit, reagent #3, no dilution.

4.8. Western Blot Densitometry

The Western Blot images were opened in ImageJ Version 1.53 [55]. Background signal was removed by adjusting the brightness and contrast parameters. Bands were encapsulated by rectangles, labelled with “select first lane” and quantified by analyze > gels > plot lanes.

The wand function was used to select all lanes and quantify the densitometry of each band. P-ERK bands were normalized to their corresponding total ERK bands. For representation of data, the untreated, treated and treated + MM conditions were normalized to the treated well (Sandalore or LPA). Statistical comparisons were conducted using Student's *t*-tests with the *p* value indicated above each of the conditions analyzed.

4.9. WOE Dissection, RNA Extraction and Library Prep

Mice were euthanized by CO₂ and the whole olfactory epithelium (WOE) from both nares was dissected and placed into RNA Later Stabilization Solution (Fisher Scientific, Waltham, MA, USA, AM7020). Tissues were homogenized in Buffer RLT by polytron. The homogenized lysates were transferred to a gDNA Eliminator Spin column, and RNA was extracted using the RNeasy Plus Kit (Qiagen, Germantown, MD, USA, 74134). After the RW1 wash, we performed the DNaseI (Qiagen, Germantown, MD, USA, 79254) on column digestion step for 15 min, followed by a second RW1 wash. All other steps were carried out according to the RNeasy Plus Kit's standard protocol. Total RNA was submitted to the Weill Cornell Medicine Genomics Core for library prep with the NEB Ultra II Directional RNA Library Prep (plus poly A isolation module). QC was conducted using Agilent Bioanalyzer Sample QC- Nanogel and NanoDrop Spectrophotometer. Samples were sequenced on the NovaSeq6000 (Illumina, San Diego, CA, USA) on an S4 Flow Cell at 2 × 150 cycles.

4.10. RNAseq Alignment, Quantification and Differential Expression Analysis

Nextflow nf-core v3.10.1 (<https://doi.org/10.5281/zenodo.1400710>) was used for reads alignment and quantification. More specifically, sequences were aligned with STAR [56] against GRCm38, and gene-level read quantification was carried out via RSEM [57]. Differential expression analysis between groups was performed against all genes or olfactory receptors only using EdgeR v3.40.2 [58] in R (<http://www.R-project.org>, accessed on 15 September 2023) and *p*-values were then re-corrected by FDR. Gene nomenclature was retrieved from BioMart [59]. Data analysis, statistical testing and plotting were carried out in python (<https://ir.cwi.nl/pub/5008>, accessed on 15 September 2023).

4.11. Principal Component Analysis

To calculate the principal component analysis (PCA) for our single-cell RNA sequencing data, we utilized the Scanpy library [60]. The AnnData object containing the preprocessed gene expression matrix underwent normalization, scaling and selection of highly variable genes. We then applied the PCA algorithm using the Scanpy function `sc.tl.pca`, with the `svd_solver` parameter set to 'arpack' to perform the singular value decomposition (SVD). This method projected the high-dimensional data into a lower-dimensional space, retaining the most significant features in terms of variance. The resulting PCA coordinates were stored and used to calculate Euclidean distances.

4.12. Visualization via UMAP

The scRNAseq data processing for UMAP dimensional reduction involved initial loading of count data. Quality control steps were implemented to filter cells and genes based on QC metrics, including a minimum of 200 genes per cell and a minimum of 3 cells per gene. Normalization procedures, such as log transformation and identification of highly variable genes, were performed with parameters set to minimum mean count of 0.0125, maximum mean count of 3 and minimum dispersion of 0.5. Unwanted sources of variation, including total counts and mitochondrial gene expression, were regressed out, and the data were scaled and subjected to principal component analysis (PCA) with the number of principal components (PCs) set to 40. Subsequently, nearest neighbor identification and clustering were performed using the Leiden algorithm with a resolution of 0.2, and potential lineage relationships between clusters were inferred via Partition-based Graph Abstraction (PAGA). UMAP was then applied for dimensionality reduction and visualization with the number of PCs set to 40, and clusters were visualized on the UMAP plot colored

by metadata variables. Finally, UMAP coordinates were extracted and combined with metadata for visualization of gene expression levels of specific genes of interest on the UMAP plot.

4.13. Identification of the OR Expressed in Each OSN

The characterization of OR choice in each mOSN is conducted following the method described previously [36]. Briefly, for each given mOSN, the highest expressing OR is determined to be the sole expression OR.

4.14. OR Pair-Wise Comparison

The pairwise comparison of OR was conducted across two different measurements: individual gene expression and Euclidean distance comparison between open and closed nares. Firstly, the pairs of OR comparison are obtained by generating all matches of open and closed nares cells expressing the same OR. First, for each given pair, the expression levels of OR genes were analyzed between open and closed nares using log-fold change calculations, providing insights into differential expression patterns. Secondly, Euclidean distance measurements were employed to assess the overall similarity or dissimilarity in gene expression profiles between cells from open and closed nares. This analysis enabled the characterization of the spatial relationships between cells in the scRNAseq dataset. Violin plots were generated to visualize the distributions of log-fold changes, facilitating the comparison of gene expression patterns across OR subsets that were upregulated and downregulated in the *iRhom2*^{-/-}.

4.15. OR Population Comparison

We examined each OR gene individually, assessing the counts of cells associated with open and closed nares to gauge relative abundance of OR with and without odor stimulation. The log_{1p} was calculated between nares to capture the fold change in counts between total number of cells from closed and open nares. This transformation offers a nuanced representation of fold changes without addressing issues with extreme values. To ensure comparability across receptors, we normalized the log_{1p} values based on the proportion of counts each OR contributes to the total counts across all cells. This normalization procedure standardized the effect size (fold change) to account for variations in counts across ORs, facilitating the identification of fold change with significant count alterations between open and closed nares. Ultimately, these normalized log_{1p} fold change values were used in characterizing the relative counts of OR genes in response to nares occlusion.

4.16. RNAseq Data Analysis

RNAseq analyses were performed in python (versions 3.8) and R (version 4.2). Single-cell analyses were performed in python (versions 3.8) using Scanpy package (version 1.8.2) [60]. Custom scripts for data analysis and visualization were built using open-source python libraries (pandas, numpy, matplotlib, plotly, sklearn, scipy, seaborn and itertools). Scripts to replicate data analysis are available at https://github.com/Justice-Lu/iRhom2_Analysis (accessed on 15 September 2023).

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/ijms25116079/s1>.

Author Contributions: Conceptualization, S.A.A., C.P.B. and J.E.S.; methodology, S.A.A., A.I.R. and H.-Y.L.; software, H.-Y.L.; validation, S.A.A., H.-Y.L., J.E.S., H.M. and C.P.B.; formal analysis, S.A.A. and H.-Y.L.; investigation, S.A.A., A.I.R., H.-Y.L. and S.M.; resources, C.P.B., J.E.S., S.M. and H.M.; data curation, H.-Y.L.; writing—original draft preparation, S.A.A. and C.P.B.; writing—review and editing, all authors; visualization, S.A.A., S.M. and H.-Y.L.; supervision, C.P.B., J.E.S. and H.M.; project administration, C.P.B., J.E.S. and H.M.; funding acquisition, C.P.B., J.E.S., S.M. and H.M. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Institutes of Health [NIGMS R35 GM134907 to C.P.B. and NIDCD R01 DC020353 and R01 DC021585 to H.M.]. H.M. acknowledges support from the NSF/CIHR/DFG/FRQ/UKRI-MRC Next Generation Networks for Neuroscience Program (Award #2014217). S.A.A. and A.I.R. were supported by a Medical Scientist Training Program grant from the National Institute of General Medical Sciences of the National Institutes of Health to the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program [T32GM007739] and S.A.A. received support from the Hospital for Special Surgery Rheumatology training grant T32AR071302 from NIH-NIAMS. S.M. and the Laboratory of Comparative Pathology at the Memorial Sloan Kettering Cancer Center were supported by the National Cancer Institute Cancer Center Support Grant [P30 CA008748]. The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the NIH/NIGMS/NIAMS/NIDCD.

Institutional Review Board Statement: All animal studies reported here were approved by the Internal Animal Care and Use Committee (IACUC) of the Hospital for Special Surgery and Weill Cornell Medicine, New York, NY, 10021, USA (protocol number 2020-0021, entitled “Role of iRhoms/ADAM17 in the olfactory system”, approval date 12 July 2023).

Informed Consent Statement: Not applicable.

Data Availability Statement: The raw and processed RNA-Seq datasets generated as part of this study are available from NCBI GEO at GSE268171. The single-cell RNAseq of mouse olfactory epithelium is publicly available at GSE151346. An additional single-cell RNAseq dataset of mOSNs of wildtype and unilateral naris occlusion is also publicly available at GSE173947.

Acknowledgments: We thank Alejandra Vela Morena for excellent technical assistance, Jaqueline Candelier, John D’Allara and Maria Jiao from the Laboratory of Comparative Pathology at Memorial Sloan Kettering for histology sectioning and staining, and the Weill Cornell Genomics Resources Core Facility. We thank John Blenis for providing the HaCaT cells and Michael Nitabach for providing the Sandalore. We also thank Stefan Lichtenthaler and Johanna Tüshaus for helpful insights and comments during the course of this study.

Conflicts of Interest: C.P.B. holds a patent on a method of identifying agents for combination with inhibitors of iRhoms. C.P.B. and the Hospital for Special Surgery have identified iRhom2 inhibitors and have co-founded the start-up company SciRhom in Munich to commercialize these inhibitors. H.M. has received royalties from Chemcom, research grants from Givaudan and consultant fees from Kao.

References

- McIlwain, D.R.; Lang, P.A.; Maretzky, T.; Hamada, K.; Ohishi, K.; Maney, S.K.; Berger, T.; Murthy, A.; Duncan, G.; Xu, H.C.; et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. *Science* **2012**, *335*, 229–232. [[CrossRef](#)] [[PubMed](#)]
- Adrain, C.; Zettl, M.; Christova, Y.; Taylor, N.; Freeman, M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. *Science* **2012**, *335*, 225–228. [[CrossRef](#)] [[PubMed](#)]
- Siggs, O.M.; Xiao, N.; Wang, Y.; Shi, H.; Tomisato, W.; Li, X.; Xia, Y.; Beutler, B. iRhom2 is required for the secretion of mouse TNFalpha. *Blood* **2012**, *119*, 5769–5771. [[CrossRef](#)] [[PubMed](#)]
- Christova, Y.; Adrain, C.; Bambrough, P.; Ibrahim, A.; Freeman, M. Mammalian iRhoms have distinct physiological functions including an essential role in TACE regulation. *EMBO Rep.* **2013**, *14*, 884–890. [[CrossRef](#)] [[PubMed](#)]
- Li, X.; Maretzky, T.; Weskamp, G.; Monette, S.; Qing, X.; Issuree, P.D.; Crawford, H.C.; McIlwain, D.R.; Mak, T.W.; Salmon, J.E.; et al. iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling. *Proc. Natl. Acad. Sci. USA* **2015**, *112*, 6080–6085. [[CrossRef](#)]
- Grieve, A.G.; Xu, H.; Kunzel, U.; Bambrough, P.; Sieber, B.; Freeman, M. Phosphorylation of iRhom2 at the plasma membrane controls mammalian TACE-dependent inflammatory and growth factor signalling. *eLife* **2017**, *6*, e23968. [[CrossRef](#)] [[PubMed](#)]
- Badenes, M.; Burbridge, E.; Oikonomidi, I.; Amin, A.; de Carvalho, E.; Kosack, L.; Domingos, P.; Faisca, P.; Adrain, C. The ADAM17 sheddase complex regulator iTAP modulates inflammation, epithelial repair, and tumor growth. *bioRxiv* **2022**. [[CrossRef](#)]
- Cavadas, M.; Oikonomidi, I.; Gaspar, C.J.; Burbridge, E.; Badenes, M.; Felix, I.; Bolado, A.; Hu, T.; Bileck, A.; Gerner, C.; et al. Phosphorylation of iRhom2 Controls Stimulated Proteolytic Shedding by the Metalloprotease ADAM17/TACE. *Cell Rep.* **2017**, *21*, 745–757. [[CrossRef](#)] [[PubMed](#)]
- Oikonomidi, I.; Burbridge, E.; Cavadas, M.; Sullivan, G.; Collis, B.; Naegel, H.; Clancy, D.; Brezinova, J.; Hu, T.; Bileck, A.; et al. iTAP, a novel iRhom interactor, controls TNF secretion by policing the stability of iRhom/TACE. *eLife* **2018**, *7*, e35032. [[CrossRef](#)]
- Kunzel, U.; Grieve, A.G.; Meng, Y.; Sieber, B.; Cowley, S.A.; Freeman, M. FRMD8 promotes inflammatory and growth factor signalling by stabilising the iRhom/ADAM17 sheddase complex. *eLife* **2018**, *7*, e35012. [[CrossRef](#)]

11. Geesala, R.; Issuree, P.D.; Maretzky, T. Novel functions of inactive rhomboid proteins in immunity and disease. *J. Leukoc. Biol.* **2019**, *106*, 823–835. [[CrossRef](#)] [[PubMed](#)]
12. Issuree, P.D.; Maretzky, T.; McIlwain, D.R.; Monette, S.; Qing, X.; Lang, P.A.; Swendeman, S.L.; Park-Min, K.H.; Binder, N.; Kalliolias, G.D.; et al. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. *J. Clin. Investig.* **2013**, *123*, 928–932. [[CrossRef](#)] [[PubMed](#)]
13. Black, R.; Rauch, C.T.; Kozlosky, C.J.; Peschon, J.J.; Slack, J.L.; Wolfson, M.F.; Castner, B.J.; Stocking, K.L.; Reddy, P.; Srinivasan, S.; et al. A metalloprotease disintegrin that releases tumour-necrosis factor- α from cells. *Nature* **1997**, *385*, 729–733. [[CrossRef](#)] [[PubMed](#)]
14. Moss, M.L.; Jin, S.-L.C.; Milla, M.E.; Burkhart, W.; Cartner, H.L.; Chen, W.-J.; Clay, W.C.; Didsbury, J.R.; Hassler, D.; Hoffman, C.R.; et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor- α . *Nature* **1997**, *385*, 733–736. [[CrossRef](#)]
15. Peschon, J.J.; Slack, J.L.; Reddy, P.; Stocking, K.L.; Sunnarborg, S.W.; Lee, D.C.; Russel, W.E.; Castner, B.J.; Johnson, R.S.; Fitzner, J.N.; et al. An essential role for ectodomain shedding in mammalian development. *Science* **1998**, *282*, 1281–1284. [[CrossRef](#)] [[PubMed](#)]
16. Blobel, C.P. ADAMs: Key players in EGFR-signaling, development and disease. *Nat. Rev. Mol. Cell Biol.* **2005**, *6*, 32–43. [[CrossRef](#)] [[PubMed](#)]
17. Saad, M.I.; Jenkins, B.J. The protease ADAM17 at the crossroads of disease: Revisiting its significance in inflammation, cancer, and beyond. *FEBS J.* **2024**, *291*, 10–24. [[CrossRef](#)] [[PubMed](#)]
18. Tushaus, J.; Muller, S.A.; Shrouder, J.; Arends, M.; Simons, M.; Plesnila, N.; Blobel, C.P.; Lichtenthaler, S.F. The pseudoprotease iRhom1 controls ectodomain shedding of membrane proteins in the nervous system. *FASEB J.* **2021**, *35*, e21962. [[CrossRef](#)] [[PubMed](#)]
19. Buck, L.; Axel, R. A novel multigene family may encode odorant receptors: A molecular basis for odor recognition. *Cell* **1991**, *65*, 175–187. [[CrossRef](#)]
20. Zhang, X.; Firestein, S. The olfactory receptor gene superfamily of the mouse. *Nat. Neurosci.* **2002**, *5*, 124–133. [[CrossRef](#)]
21. Shykind, B.M.; Rohani, S.C.; O'Donnell, S.; Nemes, A.; Mendelsohn, M.; Sun, Y.; Axel, R.; Barnea, G. Gene switching and the stability of odorant receptor gene choice. *Cell* **2004**, *117*, 801–815. [[CrossRef](#)]
22. Mombaerts, P. Odorant receptor gene choice in olfactory sensory neurons: The one receptor-one neuron hypothesis revisited. *Curr. Opin. Neurobiol.* **2004**, *14*, 31–36. [[CrossRef](#)] [[PubMed](#)]
23. Van der Linden, C.J.; Gupta, P.; Bhuiya, A.I.; Riddick, K.R.; Hossain, K.; Santoro, S.W. Olfactory Stimulation Regulates the Birth of Neurons That Express Specific Odorant Receptors. *Cell Rep.* **2020**, *33*, 108210. [[CrossRef](#)]
24. Santoro, S.W.; Dulac, C. The activity-dependent histone variant H2BE modulates the life span of olfactory neurons. *eLife* **2012**, *1*, e00070. [[CrossRef](#)] [[PubMed](#)]
25. Schoenfeld, T.A.; Cleland, T.A. The anatomical logic of smell. *Trends Neurosci.* **2005**, *28*, 620–627. [[CrossRef](#)]
26. Brann, D.H.; Tsukahara, T.; Weinreb, C.; Lipovsek, M.; Van den Berge, K.; Gong, B.; Chance, R.; Macaulay, I.C.; Chou, H.J.; Fletcher, R.B.; et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. *Sci. Adv.* **2020**, *6*, eabc5801. [[CrossRef](#)]
27. Maretzky, T.; McIlwain, D.R.; Issuree, P.D.; Li, X.; Malapeira, J.; Amin, S.; Lang, P.A.; Mak, T.W.; Blobel, C.P. iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 11433–11438. [[CrossRef](#)] [[PubMed](#)]
28. Inoue, A.; Ishiguro, J.; Kitamura, H.; Arima, N.; Okutani, M.; Shuto, A.; Higashiyama, S.; Ohwada, T.; Arai, H.; Makide, K.; et al. TGF α shedding assay: An accurate and versatile method for detecting GPCR activation. *Nat. Methods* **2012**, *9*, 1021–1029. [[CrossRef](#)]
29. Maretzky, T.; Evers, A.; Zhou, W.; Swendeman, S.L.; Wong, P.M.; Rafii, S.; Reiss, K.; Blobel, C.P. Migration of growth factor-stimulated epithelial and endothelial cells depends on EGFR transactivation by ADAM17. *Nat. Commun.* **2011**, *2*, 229. [[CrossRef](#)]
30. Ohtsu, H.; Dempsey, P.J.; Frank, G.D.; Brailoiu, E.; Higuchi, S.; Suzuki, H.; Nakashima, H.; Eguchi, K.; Eguchi, S. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. *Arterioscler. Thromb. Vasc. Biol.* **2006**, *26*, e133–e137. [[CrossRef](#)]
31. Forrester, S.J.; Kawai, T.; O'Brien, S.; Thomas, W.; Harris, R.C.; Eguchi, S. Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System. *Annu. Rev. Pharmacol. Toxicol.* **2016**, *56*, 627–653. [[CrossRef](#)] [[PubMed](#)]
32. Gschwind, A.; Hart, S.; Fischer, O.M.; Ullrich, A. TACE cleavage of proamphiregulin regulates GPCR-induced proliferation and motility of cancer cells. *EMBO J.* **2003**, *22*, 2411–2421. [[CrossRef](#)] [[PubMed](#)]
33. Mifune, M.; Ohtsu, H.; Suzuki, H.; Nakashima, H.; Brailoiu, E.; Dun, N.J.; Frank, G.D.; Inagami, T.; Higashiyama, S.; Thomas, W.G.; et al. G protein coupling and second messenger generation are indispensable for metalloprotease-dependent, heparin-binding epidermal growth factor shedding through angiotensin II type-1 receptor. *J. Biol. Chem.* **2005**, *280*, 26592–26599. [[CrossRef](#)] [[PubMed](#)]
34. Inoue, A.; Arima, N.; Ishiguro, J.; Prestwich, G.D.; Arai, H.; Aoki, J. LPA-producing enzyme PA-PLA(1) α regulates hair follicle development by modulating EGFR signalling. *EMBO J.* **2011**, *30*, 4248–4260. [[CrossRef](#)] [[PubMed](#)]

35. Busse, D.; Kudella, P.; Gruning, N.M.; Gisselmann, G.; Stander, S.; Luger, T.; Jacobsen, F.; Steinstrasser, L.; Paus, R.; Gkogkolou, P.; et al. A synthetic sandalwood odorant induces wound-healing processes in human keratinocytes via the olfactory receptor OR2AT4. *J. Investig. Dermatol.* **2014**, *134*, 2823–2832. [[CrossRef](#)]
36. Tsukahara, T.; Brann, D.H.; Pashkovski, S.L.; Guitchounts, G.; Bozza, T.; Datta, S.R. A transcriptional rheostat couples past activity to future sensory responses. *Cell* **2021**, *184*, 6326–6343.e32. [[CrossRef](#)] [[PubMed](#)]
37. Fischl, A.M.; Heron, P.M.; Stromberg, A.J.; McClintock, T.S. Activity-dependent genes in mouse olfactory sensory neurons. *Chem. Senses* **2014**, *39*, 439–449. [[CrossRef](#)] [[PubMed](#)]
38. Oztokatli, H.; Hornberg, M.; Berghard, A.; Bohm, S. Retinoic acid receptor and CNGA2 channel signaling are part of a regulatory feedback loop controlling axonal convergence and survival of olfactory sensory neurons. *FASEB J.* **2012**, *26*, 617–627. [[CrossRef](#)] [[PubMed](#)]
39. Bennett, M.K.; Kulaga, H.M.; Reed, R.R. Odor-evoked gene regulation and visualization in olfactory receptor neurons. *Mol. Cell. Neurosci.* **2010**, *43*, 353–362. [[CrossRef](#)]
40. Wang, Q.; Titlow, W.B.; McClintock, D.A.; Stromberg, A.J.; McClintock, T.S. Activity-Dependent Gene Expression in the Mammalian Olfactory Epithelium. *Chem. Senses* **2017**, *42*, 611–624. [[CrossRef](#)]
41. Ibarra-Soria, X.; Nakahara, T.S.; Lilue, J.; Jiang, Y.; Trimmer, C.; Souza, M.A.; Netto, P.H.; Ikegami, K.; Murphy, N.R.; Kusma, M.; et al. Variation in olfactory neuron repertoires is genetically controlled and environmentally modulated. *eLife* **2017**, *6*, e21476. [[CrossRef](#)] [[PubMed](#)]
42. D'Hulst, C.; Mina, R.B.; Gershon, Z.; Jamet, S.; Cerullo, A.; Tomoiaga, D.; Bai, L.; Belluscio, L.; Rogers, M.E.; Sirotin, Y.; et al. MouSensor: A Versatile Genetic Platform to Create Super Sniffer Mice for Studying Human Odor Coding. *Cell Rep.* **2016**, *16*, 1115–1125. [[CrossRef](#)] [[PubMed](#)]
43. Livermore, A.; Hummel, T. The influence of training on chemosensory event-related potentials and interactions between the olfactory and trigeminal systems. *Chem. Senses* **2004**, *29*, 41–51. [[CrossRef](#)] [[PubMed](#)]
44. Hossain, K.; Smith, M.; Santoro, S.W. In mice, discrete odors can selectively promote the neurogenesis of sensory neuron subtypes that they stimulate. *bioRxiv* **2024**. [[CrossRef](#)] [[PubMed](#)]
45. Sarnat, H.B.; Yu, W. Maturation and Dysgenesis of the Human Olfactory Bulb. *Brain Pathol.* **2016**, *26*, 301–318. [[CrossRef](#)] [[PubMed](#)]
46. Todrank, J.; Heth, G.; Restrepo, D. Effects of in utero odorant exposure on neuroanatomical development of the olfactory bulb and odour preferences. *Proc. Biol. Sci.* **2011**, *278*, 1949–1955. [[CrossRef](#)] [[PubMed](#)]
47. Prenzel, N.; Zwick, E.; Daub, H.; Leserer, M.; Abraham, R.; Wallasch, C.; Ullrich, A. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. *Nature* **1999**, *402*, 884–888. [[CrossRef](#)] [[PubMed](#)]
48. Fischer, O.M.; Hart, S.; Gschwind, A.; Ullrich, A. EGFR signal transactivation in cancer cells. *Biochem. Soc. Trans.* **2003**, *31 Pt 6*, 1203–1208. [[CrossRef](#)] [[PubMed](#)]
49. Hart, S.; Fischer, O.M.; Prenzel, N.; Zwick-Wallasch, E.; Schneider, M.; Hennighausen, L.; Ullrich, A. GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways. *Biol. Chem.* **2005**, *386*, 845–855. [[CrossRef](#)]
50. Watt, W.C.; Storm, D.R. Odorants stimulate the ERK/mitogen-activated protein kinase pathway and activate cAMP-response element-mediated transcription in olfactory sensory neurons. *J. Biol. Chem.* **2001**, *276*, 2047–2052. [[CrossRef](#)]
51. Orecchioni, M.; Kobiyama, K.; Winkels, H.; Ghosheh, Y.; McArdle, S.; Mikulski, Z.; Kiosses, W.B.; Fan, Z.; Wen, L.; Jung, Y.; et al. Olfactory receptor 2 in vascular macrophages drives atherosclerosis by NLRP3-dependent IL-1 production. *Science* **2022**, *375*, 214–221. [[CrossRef](#)] [[PubMed](#)]
52. Vadevoo, S.M.P.; Gunassekaran, G.R.; Lee, C.; Lee, N.; Lee, J.; Chae, S.; Park, J.Y.; Koo, J.; Lee, B. The macrophage odorant receptor Olfr78 mediates the lactate-induced M2 phenotype of tumor-associated macrophages. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2102434118. [[CrossRef](#)] [[PubMed](#)]
53. Rabinowitsch, A.I.; Maretzky, T.; Weskamp, G.; Haxaire, C.; Tueshaus, J.; Lichtenthaler, S.F.; Monette, S.; Blobel, C.P. Analysis of the function of ADAM17 in iRhom2 curly-bare and tylosis with esophageal cancer mutant mice. *J. Cell Sci.* **2023**, *136*, jcs260910. [[CrossRef](#)] [[PubMed](#)]
54. Bankhead, P.; Loughrey, M.B.; Fernandez, J.A.; Dombrowski, Y.; McArt, D.G.; Dunne, P.D.; McQuaid, S.; Gray, R.T.; Murray, L.J.; Coleman, H.G.; et al. QuPath: Open source software for digital pathology image analysis. *Sci. Rep.* **2017**, *7*, 16878. [[CrossRef](#)] [[PubMed](#)]
55. Schneider, C.A.; Rasband, W.S.; Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. *Nat. Methods* **2012**, *9*, 671–675. [[CrossRef](#)] [[PubMed](#)]
56. Dobin, A.; Davis, C.A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.; Gingeras, T.R. STAR: Ultrafast universal RNA-seq aligner. *Bioinformatics* **2013**, *29*, 15–21. [[CrossRef](#)]
57. Li, B.; Dewey, C.N. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. *BMC Bioinform.* **2011**, *12*, 323. [[CrossRef](#)] [[PubMed](#)]
58. Robinson, M.D.; McCarthy, D.J.; Smyth, G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **2010**, *26*, 139–140. [[CrossRef](#)]

-
59. Smedley, D.; Haider, S.; Ballester, B.; Holland, R.; London, D.; Thorisson, G.; Kasprzyk, A. BioMart—Biological queries made easy. *BMC Genom.* **2009**, *10*, 22. [[CrossRef](#)]
 60. Wolf, F.A.; Angerer, P.; Theis, F.J. SCANPY: Large-scale single-cell gene expression data analysis. *Genome Biol.* **2018**, *19*, 15. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.